| Title | Author(s) | Issue date | ???itemlist.??? |
| Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study | Gamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H.; Pavlidis, N.; Verweij, J.; Sessa, C.; Kaye, S.; Roelvink, M.; Wanders, J.; Hanauske, A. | 24-Nov-2015 | - |
| Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG) | Pavlidis, N.; Aamdal, S.; Awada, A.; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; van Oosterom, A.; Morant, R.; Wanders, J.; Hanauske, A. R. | 24-Nov-2015 | - |
| EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group | Dirix, L. Y.; Tonnesen, F.; Cassidy, J.; Epelbaum, R.; ten Bokkel Huinink, W. W.; Pavlidis, N.; Sorio, R.; Gamucci, T.; Wolff, I.; Te Velde, A.; Lan, J.; Verweij, J. | 24-Nov-2015 | - |
| Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups | McLeod, H. L.; Murray, L. S.; Wanders, J.; Setanoians, A.; Graham, M. A.; Pavlidis, N.; Heinrich, B.; ten Bokkel Huinink, W. W.; Wagener, D. J.; Aamdal, S.; Verweij, J. | 24-Nov-2015 | - |
| Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors | Gelderblom, H.; Salazar, R.; Verweij, J.; Pentheroudakis, G.; de Jonge, M. J.; Devlin, M.; van Hooije, C.; Seguy, F.; Obach, R.; Prunonosa, J.; Principe, P.; Twelves, C. | 24-Nov-2015 | - |
| Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group | Hanauske, A. R.; Catimel, G.; Aamdal, S.; ten Bokkel Huinink, W.; Paridaens, R.; Pavlidis, N.; Kaye, S. B.; te Velde, A.; Wanders, J.; Verweij, J. | 24-Nov-2015 | - |
| Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group | Verweij, J.; Wanders, J.; Nielsen, A. L.; Pavlidis, N.; Calabresi, F.; ten Bokkel Huinink, W.; Bruntsch, U.; Piccart, M.; Franklin, H.; Kaye, S. B. | 24-Nov-2015 | - |
| Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies | Schellens, J. H.; Heinrich, B.; Lehnert, M.; Gore, M. E.; Kaye, S. B.; Dombernowsky, P.; Paridaens, R.; van Oosterom, A. T.; Verweij, J.; Loos, W. J.; Calvert, H.; Pavlidis, N.; Cortes-Funes, H.; Wanders, J.; Roelvink, M.; Sessa, C.; Selinger, K.; Wissel, P. S.; Gamucci, T.; Hanauske, A. R. | 24-Nov-2015 | - |
| Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9 | Schellens, J. H.; Dombernowsky, P.; Cassidy, J.; Epelbaum, R.; Dirix, L.; Cox, E. H.; Wanders, J.; Calabresi, F.; Paridaens, R.; Monfardini, S.; Wolff, J.; Loos, W. J.; Verweij, J.; Pavlidis, N.; Hanauske, A. R. | 24-Nov-2015 | - |
| A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG) | Pavlidis, N.; Hanauske, A. R.; Gamucci, T.; Smyth, J.; Lehnert, M.; te Velde, A.; Lan, J.; Verweij, J. | 24-Nov-2015 | - |
| Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group | Kaplan, S.; Hanauske, A. R.; Pavlidis, N.; Bruntsch, U.; te Velde, A.; Wanders, J.; Heinrich, B.; Verweij, J. | 24-Nov-2015 | - |
